Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Change In Role Of Senior Management Personnel

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that our current Site Lead India Operations - Ms. Mina Patel is completing her international assignment on July 31, 2024. She will be transitioning from the said role with effect from close of business hours July 31, 2024, as she takes up another responsibility within AstraZeneca group. Further, we wish to inform that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Srikanth B.S. as Site Lead, India Operations with effect from August 1, 2024.
03-07-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Please find the enclosed document of the Company as per the captioned subject for your reference.
01-07-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) and other applicable of SEBI (LODR) Regulations, 2015, we would like to inform you that the RTA of the Company have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.
27-06-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Record Date For Payment Of Final Dividend

Further to our intimation dated May 27, 2024, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of Final Dividend for the financial year is July 5, 2024. The Final Dividend, if approved by the shareholders, shall be paid/ dispatched to the shareholders on or before September 6, 2024.
25-06-2024
Bigul

AstraZeneca's Imfinzi fails in late-stage trial to treat lung cancer cases

Imfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response
25-06-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Please find the attached disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.
21-06-2024
Bigul

AstraZeneca chemotherapy gets US nod for certain type of endometrial cancer

Endometrial cancer ranks as the fourth most prevalent cancer among women in the US. In 2022, it affected more than 66,000 patients
17-06-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the RTA of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for loss of share certificate from the legal representative of the claimant.
14-06-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window

This is to inform you that in accordance with the provisions of SEBI (PIT) Regulations, 2015 read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the equity shares of the Company will be closed from June 16, 2024 and the same shall reopen after 48 hours from the declaration of un-audited financial results of the Company for the quarter ending June 30, 2024.
13-06-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

We are enclosing herewith the certificate dated June 3, 2024 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
07-06-2024
Next Page
Close

Let's Open Free Demat Account